Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer

Documenti analoghi

• Real‐world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non‐muscle invasive bladder cancer—Implications for global shortage
  di: Amandeep Arora, et al.
  Pubblicazione: (2025)
• Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
  di: Arjun Pon Avudaiappan, et al.
  Pubblicazione: (2024)
• Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer
  di: Kylie Yen‐Yi Lim, et al.
  Pubblicazione: (2025)
• Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia
  di: Alison Hiong, et al.
  Pubblicazione: (2025)
• Haematuria cancer risk score as a predictor of muscle‐invasive bladder cancer
  di: Serdar Turan, et al.
  Pubblicazione: (2025)